Tolvaptan (brand name Jynarque) is the only FDA-approved drug specifically for ADPKD. It slows kidney growth by ~50% but comes with significant side effects including extreme thirst, massive urine output, and liver toxicity risk requiring ongoing monitoring.
Background
Tolvaptan's journey to PKD approval took over 15 years. Otsuka Pharmaceutical first tested it in ADPKD in the landmark TEMPO 3:4 trial (2007–2012), which enrolled 1,445 patients across 129 sites worldwide. The results were groundbreaking: tolvaptan reduced the rate of kidney growth by 49% compared to placebo. However, FDA initially hesitated due to liver safety concerns — three patients developed serious liver injury. It took additional studies (TEMPO 4:4 extension, REPRISE trial in later-stage disease) before FDA granted approval in April 2018, making it the first and still only drug specifically approved for ADPKD.
How It Works
Vasopressin (ADH) binds V2 receptors in kidney collecting duct cells, activating adenylyl cyclase and raising intracellular cAMP. In ADPKD, elevated cAMP drives two pathological processes: (1) CFTR-mediated chloride and fluid secretion into cysts, causing them to expand, and (2) cell proliferation of cyst-lining epithelial cells via Ras/ERK pathway activation. Tolvaptan blocks the V2 receptor, reducing cAMP levels and thereby inhibiting both cyst fluid accumulation and cyst cell growth. The downside: blocking V2 also prevents water reabsorption in the collecting duct, causing massive water diuresis (aquaresis) — patients typically produce 4–8 liters of dilute urine per day.
Clinical Trial Details
TEMPO 3:4 (NCT00428948): 1,445 ADPKD patients, 3 years, showed 49% reduction in TKV growth rate (2.8% vs 5.5% per year). REPRISE (NCT02160145): 1,370 patients with later-stage CKD (eGFR 25–65), showed slower eGFR decline (-2.34 vs -3.61 ml/min/year). TEMPO 4:4: open-label extension confirming sustained benefit over 5+ years. Based on combined data, FDA approved tolvaptan (as Jynarque) in April 2018 for adults with rapidly progressive ADPKD. Japan approved it in 2014, Europe (as Jinarc) in 2015.
Why It's Promising
Tolvaptan proved that PKD progression can be pharmaceutically slowed — a landmark achievement. It reduces kidney growth rate by ~50% and slows eGFR decline by about 1 ml/min/year. For rapidly progressive patients, this can delay dialysis by several years. It also established the regulatory framework and clinical trial endpoints (TKV, eGFR slope) that all subsequent PKD drugs now use.
Limitations & Concerns
Significant tolerability burden: polyuria (4–8L urine/day), polydipsia (extreme thirst), nocturia (waking multiple times at night to urinate). Hepatotoxicity risk requires monthly liver function tests for 18 months, then quarterly (FDA REMS program). Approximately 5–10% of patients on tolvaptan develop elevated liver enzymes. Many patients discontinue due to quality-of-life impact. High cost (~$150,000/year in the US). Not suitable for patients with liver disease. Only indicated for 'rapidly progressive' ADPKD — defining which patients qualify remains debated.